PMID- 16269090
OWN - NLM
STAT- MEDLINE
DCOM- 20060329
LR  - 20181113
IS  - 1465-993X (Electronic)
IS  - 1465-9921 (Print)
IS  - 1465-9921 (Linking)
VI  - 6
IP  - 1
DP  - 2005 Nov 4
TI  - Isolation of human beta-defensin-4 in lung tissue and its increase in lower 
      respiratory tract infection.
PG  - 130
AB  - BACKGROUND: Human beta-defensin-4 (hBD-4), a new member of the beta-defensin 
      family, was discovered by an analysis of the genomic sequence. The objective of 
      this study was to clarify hBD-4 expression in human lung tissue, along with the 
      inducible expression in response to infectious stimuli, localization, and 
      antimicrobial activities of hBD-4 peptides. We also investigated the 
      participation of hBD-4 in chronic lower respiratory tract infections (LRTI) by 
      measuring the concentrations of hBD-4 peptides in human bronchial epithelial 
      lining fluid (ELF). METHODS: The antimicrobial activity of synthetic hBD-4 
      peptides against E. coli and P. aeruginosa was measured by radial diffusion and 
      colony count assays. We identified hBD-4 in homogenated human lung tissue by 
      reverse-phase high-performance liquid chromatography coupled with a 
      radioimmunoassay (RIA). Localization of hBD-4 was studied through 
      immunohistochemical analysis (IHC). We investigated the effects of 
      lipopolysaccharide (LPS) on hBD-4 expression and its release from small airway 
      epithelial cells (SAEC). We collected ELF from patients with chronic LRTI using 
      bronchoscopic microsampling to measure hBD-4 concentrations by RIA. RESULTS: 
      hBD-4 exhibited salt-sensitive antimicrobial activity against P. aeruginosa. We 
      detected the presence of hBD-4 peptides in human lung tissue. IHC demonstrated 
      the localization of hBD-4-producing cells in bronchial and bronchiolar 
      epithelium. The levels of hBD-4 peptides released from LPS-treated SAECs were 
      higher than those of untreated control cells. ELF hBD-4 was detectable in 4 of 6 
      patients with chronic LRTI, while the amounts in controls were all below the 
      detectable level. CONCLUSION: This study suggested that hBD-4 plays a significant 
      role in the innate immunity of the lower respiratory tract.
FAU - Yanagi, Shigehisa
AU  - Yanagi S
AD  - Third Department of Internal Medicine, Miyazaki University School of Medicine, 
      Miyazaki 889-1692, Japan. shigeyana2002@yahoo.co.jp
FAU - Ashitani, Jun-ichi
AU  - Ashitani J
FAU - Ishimoto, Hiroshi
AU  - Ishimoto H
FAU - Date, Yukari
AU  - Date Y
FAU - Mukae, Hiroshi
AU  - Mukae H
FAU - Chino, Naoyoshi
AU  - Chino N
FAU - Nakazato, Masamitsu
AU  - Nakazato M
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20051104
PL  - England
TA  - Respir Res
JT  - Respiratory research
JID - 101090633
RN  - 0 (DEFB4A protein, human)
RN  - 0 (beta-Defensins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Female
MH  - Humans
MH  - Lung/*metabolism
MH  - Male
MH  - Respiratory Tract Infections/*metabolism
MH  - Up-Regulation
MH  - beta-Defensins/*metabolism
PMC - PMC1298335
EDAT- 2005/11/05 09:00
MHDA- 2006/03/30 09:00
PMCR- 2005/11/04
CRDT- 2005/11/05 09:00
PHST- 2005/07/21 00:00 [received]
PHST- 2005/11/04 00:00 [accepted]
PHST- 2005/11/05 09:00 [pubmed]
PHST- 2006/03/30 09:00 [medline]
PHST- 2005/11/05 09:00 [entrez]
PHST- 2005/11/04 00:00 [pmc-release]
AID - 1465-9921-6-130 [pii]
AID - 10.1186/1465-9921-6-130 [doi]
PST - epublish
SO  - Respir Res. 2005 Nov 4;6(1):130. doi: 10.1186/1465-9921-6-130.